Latest Ratios: P/E Ratio -9.6x · EV/EBITDA N/A · ROE -30.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.0B | $4.7B | $3.3B | $5.0B | $3.2B | $6.1B | $10.1B | $3.5B | $1.4B | $941M | $248M |
| Enterprise Value | $6.0B | $4.8B | $3.2B | $4.8B | $3.2B | $5.4B | $9.0B | $2.6B | $914M | $701M | $-67183394 |
| P/E Ratio → | -9.57 | — | — | — | — | 16.12 | — | 52.06 | — | — | — |
| P/S Ratio | 1700.63 | 1343.50 | 94.87 | 13.40 | 7248.62 | 6.67 | 14043.89 | 11.97 | 438.65 | 22.94 | 48.09 |
| P/B Ratio | 2.90 | 2.45 | 1.72 | 2.63 | 1.69 | 2.54 | 6.07 | 3.69 | 3.49 | 5.01 | 1.07 |
| P/FCF | — | — | — | — | — | 13.32 | — | 69.36 | — | — | — |
| P/OCF | — | — | — | — | — | 11.30 | — | 61.18 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1354.81 | 92.74 | 13.00 | 7322.33 | 5.91 | 12503.98 | 8.90 | 292.48 | 17.09 | -13.01 |
| EV / EBITDA | — | — | — | — | — | 13.78 | — | 50.06 | — | — | — |
| EV / EBIT | — | — | — | — | — | 14.44 | — | 55.12 | — | — | — |
| EV / FCF | — | — | — | — | — | 11.80 | — | 51.53 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -6537.0% | -6537.0% | -215.0% | 64.8% | -25186.7% | 88.9% | -37369.7% | 38.1% | -3541.9% | -70.3% | -717.9% |
| Operating Margin | -16191.4% | -16191.4% | -1333.0% | -60.1% | -154394.7% | 40.9% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% |
| Net Profit Margin | -16569.8% | -16569.8% | -1046.4% | -41.5% | -149122.7% | 41.4% | -48520.9% | 23.1% | -5281.1% | -166.7% | -449.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | -19.2% | -8.2% | -30.4% | 18.6% | -26.8% | 10.0% | -56.9% | -32.5% | -22.8% |
| ROA | -25.8% | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% |
| ROIC | -22.3% | -22.3% | -19.5% | -9.2% | -28.0% | 24.8% | -87.8% | 72.7% | — | — | — |
| ROCE | -26.6% | -26.6% | -21.8% | -10.5% | -28.3% | 17.1% | -25.8% | 6.4% | -44.3% | -22.3% | -28.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.57 | — | 1.02 | — | — | — |
| Net Debt / Equity | — | 0.02 | -0.04 | -0.08 | 0.02 | -0.29 | -0.67 | -0.95 | -1.16 | -1.28 | -1.36 |
| Net Debt / EBITDA | — | — | — | — | — | -1.78 | — | -17.32 | — | — | — |
| Debt / FCF | — | — | — | — | — | -1.53 | — | -17.83 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -1.82 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Quick Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Cash Ratio | 13.30 | 13.30 | 21.69 | 15.57 | 14.99 | 19.85 | 17.93 | 16.53 | 16.46 | 16.52 | 14.34 |
| Asset Turnover | — | 0.00 | 0.02 | 0.17 | 0.00 | 0.33 | 0.00 | 0.27 | 0.01 | 0.15 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 260.71 | 197.30 | — | 0.12 | 5504.95 | 0.12 | 10.28 | 23.38 | 223.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 6.2% | — | 1.9% | — | — | — |
| FCF Yield | — | — | — | — | — | 7.5% | — | 1.4% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $90M | $84M | $79M | $78M | $80M | $66M | $57M | $48M | $40M | $12M |
Clinical and Commercial Execution
According to current market data, CRSP trades at a price-to-sales ratio of 1509.11, a figure that reflects investor optimism regarding the long-term CRISPR/Cas9 platform potential rather than any near-term earnings reality, as the company currently lacks a positive P/E or meaningful EBITDA to justify traditional valuation metrics.
The extreme P/S multiple suggests that the market is pricing the company as a high-growth technology platform rather than a traditional biotech entity. Investors should monitor whether the transition to commercial-stage revenue can eventually compress these multiples to levels more consistent with established pharmaceutical peers.
Based on reported financial statements, CRSP's ROIC has remained consistently negative, hovering around -4.7% to -6.8% over the last ten quarters, which indicates that the company is currently destroying invested capital as it funds extensive clinical development programs that have yet to achieve commercial scale.
The persistent negative return on capital highlights the heavy reliance on external funding to sustain R&D intensity. Until the company can demonstrate a path toward positive operating margins through its Vertex partnership, these returns will likely remain suppressed by the high cost of clinical trial execution.
As reported in recent filings, the company's asset turnover ratio remains near zero, reflecting the fact that the vast majority of the balance sheet is comprised of cash and financial assets rather than revenue-generating operational infrastructure, which is typical for a pre-commercial or early-commercial biotech firm.
The lack of meaningful asset turnover suggests that the company has not yet optimized its manufacturing or logistics footprint for high-volume commercial delivery. Investors should look for improvements in this metric as the company activates more Authorized Treatment Centers and scales its autologous therapy supply chain.
According to recent balance sheet data, CRSP has increased its debt-to-equity ratio to 0.43 as of 2026Q1, signaling a strategic shift toward utilizing credit facilities to bridge the funding gap between clinical development and the realization of commercial profit-sharing milestones from its partnership with Vertex Pharmaceuticals.
While the current leverage remains manageable, the trend toward debt financing warrants close monitoring given the company's lack of consistent operating cash flow. The reliance on debt to fund operations increases the sensitivity of the balance sheet to interest rate fluctuations and potential capital market volatility.
The price-to-sales ratio is frequently misapplied to CRSP, as the company's revenue is derived from lumpy, non-recurring milestone payments rather than steady-state product sales, which obscures the underlying commercial progress and makes the metric an unreliable indicator of the company's true valuation or future growth trajectory.
Analysts should instead focus on the number of activated Authorized Treatment Centers and the progression of the allogeneic pipeline as more accurate leading indicators of value. Relying on P/S ratios in this context risks misinterpreting one-time collaboration inflows as sustainable commercial momentum.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRSP stock.
CRISPR Therapeutics AG's current P/E ratio is -9.6x. The historical average is 34.1x.
CRISPR Therapeutics AG's return on equity (ROE) is -30.2%. The historical average is -19.8%.
Based on historical data, CRISPR Therapeutics AG is trading at a P/E of -9.6x. Compare with industry peers and growth rates for a complete picture.
CRISPR Therapeutics AG has -6537.0% gross margin and -16191.4% operating margin.